Mervituximab Antibody Drug Conjugate in Ovarian Cancer

Mervituximab antibody drug conjugate approved. Less than 1 percent of patients who are treated Merv have to stop the therapy due to the eye issues. The side effects of blurred vision are very predictable and almost always occurring about cycle 2, day 7 to 14. If it's just not that bothersome of the patient they're able to go about and do their regular activities.